

EAPCI Certification Exam in Interventional Cardiology

Topics covered

Part I - Coronary Track - Invasive diagnostic assessment

- 1.1 - Natural history of coronary artery disease
- 1.2 - Coronary track – Invasive diagnostic assessment - Vascular access and closure
- 1.3 – Coronary track – Invasive diagnostic assessment - Invasive Coronary Angiography
- 1.4 - Coronary track – Invasive diagnostic assessment- Invasive haemodynamic assessment
- 1.5 - Coronary track – Invasive diagnostic assessment - Invasive physiological assessment of coronary artery disease
- 1.6 - Invasive imaging: cardiac catheterization and angiography
- 1.7 - Intravascular Imaging
- 1.8 - Intravascular Ultrasound
- 1.9 - Optical Coherence Tomography
- 1.10 - Endomyocardial biopsy
- 1.11 - Radiation protection
- 1.12 - Contrast agents and renal protection

Part II – Coronary Track: Percutaneous interventions - DEVICES and TOOLS

- 2.1 - Guide catheters and wires for PCI (except CTOs)
- 2.2 - Balloon angioplasty technology
- 2.3 - Coronary artery stents (including DES)
- 2.4 - Bioresorbable scaffolds
- 2.5 - Drug-coated balloons
- 2.6 - Lesion subsets
- 2.7 - Bifurcation lesions
- 2.8 - Calcified and Resistant lesions (including Rotational atherectomy)

- 2.9 - Left main coronary artery disease
- 2.10 - Chronic total occlusions (including specific guides and wires)
- 2.11 - Bypass graft disease
- 2.12 Device failure (stent thrombosis and in-stent restenosis)
- 2.13 - Interventions for stable coronary disease
- 2.14 - Interventions for patients with multivessel CAD (including hybrid approach)
- 2.15 - Interventions for ST--segment elevation acute myocardial infarction (including thrombectomy)
- 2.16 - Interventions in patients with NSTEMI-ACS
- 2.17 - Interventions for patients with diabetes mellitus
- 2.18 - Interventions for patients with chronic kidney disease
- 2.19 - Interventions with Cardiogenic shock
- 2.20 - Complications and Management
- 2.21 - Peri-Procedural and Post-Procedural Antithrombotic Pharmacotherapy
- 2.22 - Secondary prevention and follow-up

Part III: Percutaneous interventions for structural and congenital heart disease (Non-coronary Track)

- 3.1 Transcatheter Aortic Valve treatment: aortic balloon valvuloplasty and TAVI
- 3.2 Transcatheter mitral and tricuspid interventions (TMTCI)
- 3.3 Transcoronary ablation of septal hypertrophy (TASH)
- 3.4 Percutaneous pulmonary intervention (including valvuloplasty and valve implantation)
- 3.5 Atrial interventions (including Left atrial appendage occlusion and Atrial septal defect and patent foramen ovale closure)
- 3.6 Percutaneous closure of paravalvular leaks and ventricular septal defect closure
- 3.7 Cell--based regenerative therapy and Techniques of myocardial stem cell delivery
- 3.8 Cardiac catheterisation in children and adults with grown-up congenital heart disease

Part IV: Peripheral percutaneous interventions

- 4.1 Carotid, subclavian, brachiocephalic and vertebral interventions
- 4.2 Endovascular interventions for Acute Ischemic Stroke
- 4.3 Thoracic and abdominal aortic disease
- 4.4 Peripheral arterial occlusive disease
- 4.5 Renovascular interventions for arterial hypertension

Part V: Logistics, study interpretation and consensus on clinical end-points

- 5.1 Logistics - Patient information, ethics and informed consent
- 5.2 Logistics – Heart Team
- 5.3 Logistics - the cardiac catheterisation laboratory environment
- 5.4 Clinical trial design and management
- 5.5 Study understanding, statistical knowledge and data collection
- 5.6 Consensus on definitions of clinical endpoints